184 related articles for article (PubMed ID: 38663960)
1. Factors affecting heterogeneity in breast cancer microenvironment: A narrative mini review.
Ganguly A; Mukherjee S; Chatterjee K; Spada S
Int Rev Cell Mol Biol; 2024; 385():211-226. PubMed ID: 38663960
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
3. A review concerning the breast cancer-related tumour microenvironment.
Rodríguez-Bejarano OH; Parra-López C; Patarroyo MA
Crit Rev Oncol Hematol; 2024 Jul; 199():104389. PubMed ID: 38734280
[TBL] [Abstract][Full Text] [Related]
4. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer.
Liu Y; He X; Yang YI
J Biosci; 2024; 49():. PubMed ID: 38287674
[TBL] [Abstract][Full Text] [Related]
5. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
Jenkins S; Wesolowski R; Gatti-Mays ME
Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer organoids and their applications for precision cancer immunotherapy.
Guan D; Liu X; Shi Q; He B; Zheng C; Meng X
World J Surg Oncol; 2023 Oct; 21(1):343. PubMed ID: 37884976
[TBL] [Abstract][Full Text] [Related]
7. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA
Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer immune microenvironment: from pre-clinical models to clinical therapies.
Wilson BE; Gorrini C; Cescon DW
Breast Cancer Res Treat; 2022 Jan; 191(2):257-267. PubMed ID: 34731350
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of Pyroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Breast Cancer.
Wu J; Zhu Y; Luo M; Li L
Front Immunol; 2021; 12():748221. PubMed ID: 34659246
[TBL] [Abstract][Full Text] [Related]
10. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L
Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821
[TBL] [Abstract][Full Text] [Related]
11. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.
Trnkova L; Buocikova V; Mego M; Cumova A; Burikova M; Bohac M; Miklikova S; Cihova M; Smolkova B
Biomed Pharmacother; 2024 May; 174():116559. PubMed ID: 38603889
[TBL] [Abstract][Full Text] [Related]
13. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies.
Baxevanis CN; Fortis SP; Perez SA
Semin Cancer Biol; 2021 Jul; 72():76-89. PubMed ID: 31881337
[TBL] [Abstract][Full Text] [Related]
14. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
[TBL] [Abstract][Full Text] [Related]
15. A review of immune checkpoint blockade in breast cancer.
Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
[TBL] [Abstract][Full Text] [Related]
16. Combined signature of N7-methylguanosine regulators with their related genes and the tumor microenvironment: a prognostic and therapeutic biomarker for breast cancer.
Li T; Chen Z; Wang Z; Lu J; Chen D
Front Immunol; 2023; 14():1260195. PubMed ID: 37868988
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures.
Li J; Wu J; Han J
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672784
[TBL] [Abstract][Full Text] [Related]
18. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract][Full Text] [Related]
19. Unveiling the Immune Microenvironment's Role in Breast Cancer: A Glimpse into Promising Frontiers.
Kotsifaki A; Alevizopoulos N; Dimopoulou V; Armakolas A
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895012
[TBL] [Abstract][Full Text] [Related]
20. Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.
Jin J; Li Y; Zhao Q; Chen Y; Fu S; Wu J
Cell Commun Signal; 2021 May; 19(1):50. PubMed ID: 33957948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
